// App-Quantinova.ai

e24057 : Anti-Müllerian hormone (AMH) as a marker of ovarian reserve and premature ovarian insufficiency (POI) in children and women with cancer: A systematic review.

Researchers

Presenter

  • David A. Cameron

Principal Investigators

  • Richard Anderson

  • Florian Clatot

  • Isabelle Demeestere

  • Matteo Lambertini

  • Scott M Nelson

  • Fedro Peccatori

Medical Centers

  • University of Edinburgh, Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom

  • MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, United Kingdom

  • INSERM U1245, IRON Group, Centre Henri Becquerel, University Hospital, University of Normandy, Rouen, France

  • Faculty of Medicine, Brussels, Belgium

  • Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy

  • School of Medicine, Glasgow, United Arab Emirates

  • European Institute of Oncology, Milan, Italy

Locations

  • United Kingdom

  • France

  • Belgium

  • Italy

  • United Arab Emirates

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Premature ovarian failure

  • Solid malignancies

Biomarkers

  • Anti-Müllerian hormone

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved